Related references
Note: Only part of the references are listed.Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy
Salwa Bakhsh et al.
HISTOPATHOLOGY (2016)
POLE proofreading mutation, immune response and prognosis in endometrial cancer
Inge C. van Gool et al.
ONCOIMMUNOLOGY (2016)
Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?
Piera Gargiulo et al.
CANCER TREATMENT REVIEWS (2016)
Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer
Hui Zhang et al.
CELL (2016)
Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab
Alessandro D. Santin et al.
CLINICAL CANCER RESEARCH (2016)
Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis
Melissa K. McConechy et al.
CLINICAL CANCER RESEARCH (2016)
Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer
David R. Kroeger et al.
CLINICAL CANCER RESEARCH (2016)
CD103 defines intraepithelial CD8+PD1+tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma
Hagma H. Workel et al.
EUROPEAN JOURNAL OF CANCER (2016)
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
Bernhard Mlecnik et al.
IMMUNITY (2016)
Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers
Marie-Caroline Dieu-Nosjean et al.
IMMUNOLOGICAL REVIEWS (2016)
Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence A Subanalysis
Caroline C. Billingsley et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2016)
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Janice M. Mehnert et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
Eric Bouffet et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer
Inge C. Van Gool et al.
MODERN PATHOLOGY (2016)
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
Alena Gros et al.
NATURE MEDICINE (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer
Ellen Stelloo et al.
ONCOTARGET (2016)
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Marios Giannakis et al.
CELL REPORTS (2016)
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
Joseph McLaughlin et al.
JAMA ONCOLOGY (2016)
A panoply of errors: polymerase proofreading domain mutations in cancer
Emily Rayner et al.
NATURE REVIEWS CANCER (2016)
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study
Enric Domingo et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Inge C. van Gool et al.
CLINICAL CANCER RESEARCH (2015)
PD-L1 expression in small cell neuroendocrine carcinomas
Anne M. Schultheis et al.
EUROPEAN JOURNAL OF CANCER (2015)
Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+T cell responses in endometrial cancer patients
Stefania Bellone et al.
GYNECOLOGIC ONCOLOGY (2015)
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
Ellen Stelloo et al.
MODERN PATHOLOGY (2015)
Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis
E. Zeynep Erson-Omay et al.
NEURO-ONCOLOGY (2015)
Correction: Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Timothy A. Chan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Tertiary lymphoid structure-associated B cells are key players in anti-tumor immunity
Claire Germain et al.
FRONTIERS IN IMMUNOLOGY (2015)
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
Brooke E. Howitt et al.
JAMA ONCOLOGY (2015)
Climate change and non-communicable diseases
The Lancet Oncology
LANCET ONCOLOGY (2015)
Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
David N. Church et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
High and Interrelated Rates of PD-L1(+)CD14(+) Antigen-Presenting Cells and Regulatory T Cells Mark the Microenvironment of Metastatic Lymph Nodes from Patients with Cervical Cancer
A. Marijne Heeren et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
Scott D. Brown et al.
GENOME RESEARCH (2014)
Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication
Eve Shinbrot et al.
GENOME RESEARCH (2014)
Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity
Fei Duan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Assessment of a fully automated high-throughput DNA extraction method from formalin-fixed, paraffin-embedded tissue for KRAS, and BRAF somatic mutation analysis
Ronald van Eijk et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2013)
DNA polymerase ? and exonuclease domain mutations in endometrial cancer
David N. Church et al.
HUMAN MOLECULAR GENETICS (2013)
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
Nienke van Rooij et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Integrated genomic characterization of endometrial carcinoma
Gad Getz et al.
NATURE (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
In silico prediction of tumor antigens derived from functional missense mutations of the cancer gene census
Jahan S. Khalili et al.
ONCOIMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio:: Which variable determines survival of cervical cancer patients?
Ekaterina S. Jordanova et al.
CLINICAL CANCER RESEARCH (2008)
NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence
Morten Nielsen et al.
PLOS ONE (2007)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
Share Paper
